{
  "timestamp": "20250104_013548",
  "model": "gpt-4o-mini",
  "interaction_type": "answer_with_CoT",
  "question_id": "427393cb",
  "question_text": "Which of the following drug is contraindicated in a patient of myasthenia gravis: September 2008",
  "messages": [
    {
      "role": "system",
      "content": "You are a medical expert using chain-of-thought reasoning."
    },
    {
      "role": "user",
      "content": "You are a medical expert specializing in the field of Pharmacology.\n            You are a medical expert determining the final answer.\n\n                ### Instructions:\n                - Use standard medical knowledge as the primary guide.\n                - Consider enhanced information only if it aligns with consensus.\n                - If conflicting or unclear, present the most likely correct answer based on known facts.\n                - It's acceptable to show moderate confidence if the question is complex, but still choose one best answer.\n            ### Question    \n            Which of the following drug is contraindicated in a patient of myasthenia gravis: September 2008\n\n            ### Options\n            opa. Succinylcholine\nopb. Tubocurare\nopc. Pyridostigmine\nopd. Halothane\n\n### Reasoning Chains for Validation:\n- CHAIN: \"Myasthenia gravis\" -> \"autoimmune neuromuscular disorder\" -> \"characterized by weakness and fatigue\" -> \"increased risk of respiratory failure with certain drugs\" -> \"Succinylcholine causes muscle paralysis\" -> \"may exacerbate weakness in myasthenia gravis\" -> 95%\n- CHAIN: \"Myasthenia gravis\" -> \"requires careful management of neuromuscular function\" -> \"Tubocurare is a neuromuscular blocker\" -> \"can lead to respiratory muscle weakness\" -> \"not ideal for myasthenia gravis patients\" -> 90%\n- CHAIN: \"Myasthenia gravis\" -> \"treatment often includes cholinesterase inhibitors\" -> \"Pyridostigmine is a cholinesterase inhibitor\" -> \"improves neuromuscular transmission\" -> \"generally safe for myasthenia gravis\" -> 85%\n- CHAIN: \"Myasthenia gravis\" -> \"anesthetic considerations are critical\" -> \"Halothane is a volatile anesthetic\" -> \"may cause muscle relaxation\" -> \"not specifically contraindicated but requires caution\" -> 80%\n\n### Retrieved Validation Paths:\n- (Myasthenia Gravis)-MANIFESTATION_OF->(Adverse event)-ASSOCIATED_WITH->(Pharmaceutical Preparations)-INTERACTS_WITH->(Cholinesterase Inhibitors)\n- (Cholinesterase Inhibitors)-ISA->(Pharmaceutical Preparations)-INTERACTS_WITH->(SOST gene|SOST)-INTERACTS_WITH->(LRP4 gene|LRP4|CORIN)-INTERACTS_WITH->(COLQ gene|COLQ)-INTERACTS_WITH->(Pyridostigmine)\n- (Succinylcholine)-CAUSES->(Disease)-CAUSES->(Asthenia)\n- (Succinylcholine)-CAUSES->(Hereditary Diseases)-CAUSES->(Asthenia)\n- (Succinylcholine)-TREATS->(Obesity)-CAUSES->(Asthenia)\n- (Halothane)-CAUSES->(Lack of sensation)-CAUSES->(Muscle hypotonia)\n- (Halothane)-PREVENTS->(Pain)-CAUSES->(Muscle hypotonia)\n- (Halothane)-PREVENTS->(Muscle Rigidity)-CAUSES->(Muscle hypotonia)\n- (Cholinesterase Inhibitors)-TREATS->(Inflammation)-ASSOCIATED_WITH->(SOST gene|SOST)-INTERACTS_WITH->(LRP4 gene|LRP4|CORIN)-INTERACTS_WITH->(COLQ gene|COLQ)-INTERACTS_WITH->(Pyridostigmine)\n- (Pharmaceutical Preparations)-PART_OF->(Cells)-PART_OF->(Muscle)-LOCATION_OF->(Induction of neuromuscular blockade)\n\n            ### Task:\n                1. Identify the core medical principle and the most likely correct option based on consensus.\n                2. If the evidence is not perfectly clear, pick the best-supported option and explain the reasoning.\n                3. Provide a final analysis and a confidence score (0-100%).\n                \n                ### Output Format:\n                {\n                  \"final_analysis\": \"Step-by-step reasoning, prioritizing medical consensus and acknowledging complexity if present.\",\n                  \"answer\": \"Option key (e.g. opa, opb, ...)\",\n                  \"confidence\": A number between 0-100\n                }\n            "
    }
  ],
  "response": "{\n  \"final_analysis\": \"Myasthenia gravis is an autoimmune neuromuscular disorder characterized by weakness and fatigue due to impaired communication between nerves and muscles. Certain drugs can exacerbate muscle weakness in these patients. Succinylcholine is a depolarizing neuromuscular blocker that can lead to significant muscle paralysis, which poses a risk of respiratory failure in myasthenia gravis patients. Tubocurare, a non-depolarizing neuromuscular blocker, can also lead to respiratory muscle weakness, making it less ideal for these patients. Pyridostigmine, a cholinesterase inhibitor, is actually used to treat myasthenia gravis by improving neuromuscular transmission, thus it is safe and beneficial. Halothane, while a volatile anesthetic that can cause muscle relaxation, is not specifically contraindicated but requires caution. Given the potential for exacerbation of weakness, the most contraindicated drug in this context is succinylcholine. Therefore, the best-supported option is succinylcholine.\",\n  \"answer\": \"opa\",\n  \"confidence\": 95\n}",
  "metadata": {
    "topic": "Pharmacology",
    "is_multi_choice": true,
    "has_reasoning_chain": true,
    "has_enhanced_info": true,
    "model_config": "gpt-4o-mini",
    "temperature": 0.0
  }
}